WideMed Ltd. (TASE:WDMD) today announced that it and GE Healthcare will launch a new configuration of WideMed's Morpheus Hx sleep monitor, which combines GE's Mars VSL, a limited version of the Morpheus Hx, offering fewer tests compared with the current version.
The new configuration will have a lower price than the original Morpheus Hx for easier marketing in Europe and the Far East, while offering an advanced solution for monitoring patients' sleep at hospitals.
WideMed president and CEO Anya Eldan said, "In the past few months, we closely worked with GE Healthcare to expand the product's marketing network to other countries. The launch of the product's cheaper version will greatly ease the penetration of new markets, and enable us to present the company's innovation to more potential customers. We and GE are also continuing our marketing efforts in the US and Canada."
The new configuration of the Morpheus Hx expands WideMed's collaboration with GE Healthcare, following the companies' distribution and marketing agreement of April 2007. It follows WideMed's obtaining EU CE Mark certification for the Morpheus Hx. WideMed is currently seeking regulatory approval for the device in Australia, New Zealand, Singapore, and South Korea.
WideMed's share price rose 0.7% in morning trading to NIS 0.43, giving a market cap of NIS 9 million.
Published by Globes [online], Israel business news - www.globes-online.com - on January 16, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012